Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis

Tan, Eugene; Baker, Christopher; Foley, Peter

doi:10.1111/ajd.12044

Cited by 43 publications

(62 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[11][12][13][14] Our study found an association of anti-TNF-α therapy (etanercept, adalimumab and infliximab) with weight gain, and an association of ustekinumab with weight loss; with no statistical significance. With a larger cohort of patients, this association may become statistically significant.…”

Section: Discussioncontrasting

confidence: 56%

Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective

et al. 2015

View full text Add to dashboard Cite

We evaluated and compared patients' long-term adherence to biological therapies in a real-life clinical setting. Secondary aims included weight changes on biological therapy and reporting adverse effects. This prospective case-note review included 58 patients, undergoing 84 treatment series including etanercept (21), adalimumab (24), infliximab (14) and ustekinumab (25). Patients' adherence was greatest with ustekinumab (being 6.7-fold less likely to withdraw from treatment than etanercept, P = 0.014), while the difference in treatment adherence of adalimumab and infliximab compared to etanercept was not statistically significant. Adalimumab and infliximab were associated with an increase in weight, while ustekinumab was associated with weight loss compared with etanercept (not statistically significant). Long-term patient adherence to biologic therapy in patients with psoriasis is greatest with ustekinumab.

show abstract

Section: Discussioncontrasting

confidence: 56%

Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Many studies have evaluated changes in BW or BMI among patients with psoriasis treated with TNF‐α inhibitors . In these reports, the mean increase in BW was 1.5–2.6 kg at 6–7 months after the therapy with TNF‐α inhibitors.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, bodyweight (BW) has been found to influence the response of psoriasis to treatment, including biologic treatment . Recent studies have shown that treatment with tumor necrosis factor (TNF)‐α inhibitors can cause an increase in BW among patients with psoriasis and rheumatoid arthritis (RA) . However, limited information is available in terms of the effects of interleukin (IL)‐23 and IL‐17A inhibitors on BW in patients with psoriasis .…”

Section: Introductionmentioning

confidence: 99%

Effects of tumor necrosis factor‐α, interleukin‐23 and interleukin‐17A inhibitors on bodyweight and body mass index in patients with psoriasis

Takamura

Takahashi

Inoue

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Treatment with tumor necrosis factor-α inhibitors has been reported to cause weight gain in patients with psoriasis; however, limited information is available in terms of the effects of interleukin (IL)-23 and IL-17A inhibitors on bodyweight (BW) in patients with psoriasis. This study aimed to investigate the effects of infliximab, ustekinumab and secukinumab on BW and body mass index (BMI) in patients with psoriasis. We retrospectively examined changes in BW and BMI among patients treated with these biologics at our hospital. At baseline, no significant differences in BW and BMI were observed among the patients treated with infliximab (n = 18), ustekinumab (n = 30) or secukinumab (n = 20). After 7 months of the therapy, significant increases in mean BW (from 71.4 to 74.3 kg) and mean BMI (from 24.7 to 25.7) were observed in the patients treated with infliximab, whereas no significant changes were observed in those treated with ustekinumab (BW, from 70.3 to 70.1 kg; BMI, from 25.4 to 25.3) or secukinumab (BW, from 69.0 to 68.9 kg; BMI, from 25.2 to 25.2). There were no differences in the proportion of the patients who showed 75% or more improvement in the Psoriasis Area and Severity Index among the three groups. These results suggest that infliximab increases BW in the patients with psoriasis, whereas ustekinumab and secukinumab do not affect the BW in these patients.

show abstract

“…This evidence may, at least partially, give reason of (i) the enhanced TNF-α levels detected in obese subjects, with putative protective function; (ii) the body weight increase observed in psoriatic patients undergoing treatment with TNF-α inhibitors or other antipsoriatic agents decreasing TNF-α expression levels [56,[70][71][72]. However, data on TNF-α role in increased adiposity are controversial as it may also contribute to obesity counteracting insulin receptor activity and inhibiting glucose transporter (GLUT)-4, with a consequent enhancement of insulin levels that stimulates the hunger center [68].…”

Section: Tnf-αmentioning

confidence: 99%

Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity

Chiricozzi

Raimondo

Lembo

et al. 2016

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Psoriasis is a chronic skin disorder associated with several comorbid conditions. In psoriasis pathogenesis, the role of some cytokines, including TNF-α and IL-17, has been elucidated. Beside their pro-inflammatory activity, they may also affect glucose and lipid metabolism, possibly promoting insulin resistance and obesity. On the other hand, adipose tissue, secreting adipokines such as chemerin, visfatin, leptin, and adiponectin, not only regulates glucose and lipid metabolism, and endothelial cell function regulation, but it may contribute to inflammation. Areas covered: This review provides an updated 'state-of-the-art' about the reciprocal contribution of a small subset of conventional cytokines and adipokines involved in chronic inflammatory pathways, upregulated in both psoriasis and increased adiposity. A systematic search was conducted using the PubMed Medline database for primary articles. Expert commentary: Because psoriasis is associated with increased adiposity, it would be important to define the contribution of chronic skin inflammation to the onset of obesity and vice versa. Clarifying the pathogenic mechanism underlying this association, a therapeutic strategy having favorable effects on both psoriasis and increased adiposity could be identified.

show abstract

Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis

Abstract: Therapy with adalimumab and infliximab is associated with a significant increase in bodyweight and BMI.

Cited by 43 publications

References 32 publications

Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective

Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective

Effects of tumor necrosis factor‐α, interleukin‐23 and interleukin‐17A inhibitors on bodyweight and body mass index in patients with psoriasis

Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity

Contact Info

Product

Resources

About